Rectosigmoid resection during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer: morbidity of gynecologic oncology vs. colorectal team

被引:9
|
作者
Tozzi, Roberto [1 ,2 ]
Valenti, Gaetano [1 ]
Vinti, Daniele [1 ]
Campanile, Riccardo Garruto [1 ]
Cristaldi, Massimo [3 ]
Ferrari, Federico [1 ]
机构
[1] Univ Oxford, Churchill Hosp, Dept Gynaecol Oncol, Oxford, England
[2] Univ Oxford, Nuffield Dept Women & Reprod Hlth, Oxford, England
[3] Harley St Med Ctr, Dept Colorectal Surg, Abu Dhabi, U Arab Emirates
关键词
Ovarian Cancer; Surgery; Morbidity; EN-BLOC RESECTION; CYTOREDUCTIVE SURGERY; NEOADJUVANT CHEMOTHERAPY; BOWEL RESECTION; SURVIVAL; PART; IMPACT;
D O I
10.3802/jgo.2021.32.e42
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: This study investigates the specific morbidity of rectosigmoid resection (RSR) during Visceral-Peritoneal Debulking (VPD) in a consecutive series of patients with stage IIIC-IV ovarian cancer and compares the results of the colo-rectal vs. the gynaecologic oncology team. Methods: All patients with the International Federation of Gynecology and Obstetrics (FIGO) stage IIIC-IV ovarian cancer who had VPD and RSR were included in the study. Between 2009 and 2013 all operations were performed by the gynecologic oncology team alone (group 1). Since 2013 the RSR was performed by the colorectal team together with the gynecologic oncologist (group 2). All pre-operative information and surgical details were compared to exclude significant bias. Intra- and post-operative morbidity events were recorded and compared between groups. Results: One hundred and sixty-two patients had a RSR during VPD, 93 in group 1 and 69 in group 2. Groups were comparable for all pre-operative features other than: albumin (1<2) hemoglobin (2<1) and up-front surgery (1>2). Overall morbidity was 33% vs. 40% (p=0.53), bowel specific morbidity 11.8% vs. 11.5% (p=0.81), anastomotic leak 4.1% vs. 6.1% (p=0.43) and re-operation rate 9.6% vs. 6.1% (p=0.71) in groups 1 and 2, respectively. None of them were significantly different. The rate of bowel diversion was 36.5% in group 1 vs. 46.3% in group 2 (p=0.26). Conclusions: Our study failed to demonstrate any significant difference in the morbidity rate of RSR based on the team performing the surgery. These data warrant further investigation as they are interesting with regards to education, finance, and medico-legal aspects.
引用
收藏
页数:10
相关论文
共 20 条
  • [1] Morbidity and reversal rate of ileostomy after bowel resection during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer
    Tozzi, Roberto
    Casarin, Jvan
    Garruto-Campanile, Riccardo
    Majd, Hooman Soleymani
    Morotti, Matteo
    GYNECOLOGIC ONCOLOGY, 2018, 148 (01) : 74 - 78
  • [2] Feasibility of laparoscopic diaphragmatic peritonectomy during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer
    Tozzi, Roberto
    Majd, Hooman Soleymani
    Campanile, Riccardo Garruto
    Ferrari, Federico
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2020, 31 (05) : 1 - 12
  • [3] Peritonectomy and resection of mesentery during visceral-peritoneal debulking (VPD) in patients with stage IIIC-IV ovarian cancer: a phase I-II trial
    Marchetti, Matteo
    Noventa, Marco
    Spagnol, Giulia
    De Tommasi, Orazio
    Coldebella, Davide
    Tamagnini, Matteo
    Bigardi, Sofia
    Saccardi, Carlo
    Tozzi, Roberto
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A34 - A34
  • [4] Peritonectomy and resection of mesentery during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer: A phase I-II trial
    Tozzi, Roberto
    Noventa, Marco
    Spagnol, Giulia
    De Tommasi, Orazio
    Coldebella, Davide
    Tamagnini, Matteo
    Bigardi, Sofia
    Saccardi, Carlo
    Marchetti, Matteo
    EJSO, 2024, 50 (02):
  • [5] Diaphragmatic peritonectomy vs. full thickness resection with pleurectomy during Visceral-Peritoneal Debulking (VPD) in 100 consecutive patients with stage IIIC-IV ovarian cancer: A surgical-histological analysis
    Majd, Hooman Soleymani
    Ferrari, Federico
    Manek, Sanjiv
    Gubbala, Kumar
    Campanile, Riccardo Garruto
    Hardern, Kieran
    Tozzi, Roberto
    GYNECOLOGIC ONCOLOGY, 2016, 140 (03) : 430 - 435
  • [6] Survival outcomes of primary versus interval visceral-peritoneal debulking (VPD) surgery in patients with stage IIIC-IV ovarian cancer and complete resection: A cohort study
    Tozzi, R.
    Majd, H. Soleymani
    Campanile, R. Garruto
    Desgro, M.
    Morotti, M.
    Casarin, J.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 112 - 113
  • [7] Neo-adjuvant chemotherapy does not increase the rate of complete resection and does not significantly reduce the morbidity of Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer
    Tozzi, Roberto
    Giannice, Raffaella
    Cianci, Stefano
    Tardino, Sarah
    Campanile, Riccardo Garruto
    Gubbala, Kumar
    Fachechi, Giorgio
    Ferrari, Federico
    Martinek, Igor
    majd, Hooman Soleymani
    GYNECOLOGIC ONCOLOGY, 2015, 138 (02) : 252 - 258
  • [8] Feasibility of laparoscopic Visceral-Peritoneal Debulking (L-VPD) in patients with stage III-IV ovarian cancer: the ULTRA-LAP trial pilot study
    Tozzi, Roberto
    Noventa, Marco
    Saccardi, Carlo
    Spagnol, Giulia
    De Tommasi, Orazio
    Coldebella, Davide
    Marchetti, Matteo
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (02)
  • [9] Bowel resection but not bowel-related morbidity is decreased after interval debulking surgery compared to primary surgery in patients with stage IIIC-IV ovarian cancer
    Tozzi, R.
    Casarin, J.
    Baysal, A.
    Valenti, G.
    Kilic, Y.
    Majd, H. S.
    Morotti, M.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2019, 126 : 90 - 90
  • [10] Bowel resection rate but not bowel related morbidity is decreased after interval debulking surgery compared to primary surgery in patents with stage IIIC-IV ovarian cancer
    Tozzi, Roberto
    Casarin, Jvan
    Baysal, Ahmet
    Valenti, Gaetano
    Kilic, Yakup
    Majd, Hooman Soleymani
    Morotti, Matteo
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 30 (02)